PGS 키트 시장 예측(2026-2032년)

The PGS Kit Market is projected to grow by USD 1.83 billion at a CAGR of 7.75% by 2032.

PGS Kit Market: Executive Summary and Strategic Context

Preimplantation genetic screening (PGS), now more commonly described within the broader framework of preimplantation genetic testing for aneuploidy (PGT-A), is used alongside in vitro fertilization to assess chromosome number in embryos before transfer. Its clinical relevance is shaped by reproductive age, infertility diagnoses, embryo availability, laboratory capability, regulatory requirements, and the quality of genetic counseling. Adoption decisions require careful interpretation because testing can support embryo-selection workflows but does not guarantee implantation, live birth, or the absence of all genetic or developmental conditions.

Clinical Practice Is Shifting Toward More Selective, Evidence-Based Use

The landscape is moving from broad, routine application toward more individualized use based on patient characteristics, embryo cohort size, clinical history, and local evidence. Improvements in embryo culture, vitrification, biopsy procedures, sequencing, and laboratory quality systems are influencing practice, while professional guidance continues to emphasize informed consent and limitations. The distinction between screening and diagnosis is increasingly important, particularly when results are mosaic, inconclusive, or technically limited.

Artificial Intelligence Is Reshaping Embryology Workflows Without Replacing Genetic Expertise

Artificial intelligence is being applied to embryo image assessment, time-lapse interpretation, workflow prioritization, quality monitoring, and data integration. These tools may improve consistency and help laboratories organize complex information, but their clinical value depends on representative training data, external validation, explainability, cybersecurity, and governance. AI outputs should remain decision-support inputs rather than substitutes for embryologist judgment, genetic counseling, physician oversight, or confirmatory diagnostic pathways where clinically indicated.

Regional Insights: Regulation, Infrastructure, and Access Drive Differences

North America combines advanced reproductive-medicine infrastructure with strong laboratory specialization, but access, insurance coverage, and state or provincial rules vary. Europe is shaped by country-specific regulation, ethical review, and European Union data-protection expectations. Asia-Pacific includes highly developed IVF centers alongside rapidly expanding clinical capacity, with substantial differences in regulation and affordability. Latin America is characterized by uneven access, private-sector concentration, and evolving oversight. The Middle East shows growing reproductive-care capability alongside distinct legal, religious, and ethical frameworks. Africa remains highly heterogeneous, with limited advanced laboratory capacity in many settings and an important need for referral networks, training, and quality assurance.

Group Insights: Regional Blocs Create Distinct Governance and Access Conditions

ASEAN markets differ substantially in clinical infrastructure, regulation, and cross-border care, making harmonized laboratory standards valuable. BRICS members span advanced and developing reproductive-health systems, with varied approaches to genetic testing, data governance, and affordability. The European Union places strong emphasis on privacy, medical-device and laboratory compliance, and national implementation of reproductive legislation. G7 countries generally have mature clinical and research ecosystems, although reimbursement and ethical rules remain diverse. GCC countries are developing specialized fertility services within culturally specific regulatory environments. NATO members do not constitute a single healthcare or PGT policy system, but their shared security and technology context underscores the importance of resilient laboratories, secure health data, and trusted supply chains.

Country Insights: National Policy and Clinical Capacity Shape Adoption

Australia and Canada combine established fertility services with jurisdiction-specific regulation and access considerations. The United States has extensive laboratory and clinical capacity, alongside fragmented coverage and differing state policies. The United Kingdom, France, Germany, Italy, and Spain operate within structured European regulatory and ethical environments, with national differences in permitted indications, reimbursement, and service organization. Japan and South Korea have advanced assisted-reproduction capabilities, while policy, demographic priorities, and reimbursement frameworks influence use. China is expanding reproductive-health infrastructure under a closely regulated system. India has a large and diverse fertility-services ecosystem governed by evolving national standards. Brazil and Mexico show substantial private-sector activity but uneven access across regions. Russia's use of assisted reproductive technologies is shaped by national regulation, clinical capacity, and changing healthcare conditions.

Strategic Priorities for Leaders: Build Trust, Quality, and Clinical Utility

Industry leaders should establish rigorous analytical and clinical quality systems covering biopsy, sample handling, sequencing, interpretation, reporting, and proficiency testing. They should communicate clearly that PGT-A is a screening tool with defined limitations, support independent genetic counseling, and create protocols for mosaic, no-result, and discordant findings. Investment priorities should include laboratory interoperability, secure data architecture, transparent AI validation, staff training, and post-market or real-world evidence collection. Partnerships with clinicians, patient groups, regulators, and ethics experts can improve responsible adoption while access strategies should address affordability, geographic gaps, and culturally appropriate counseling.

Research Methodology: Evidence-Based Interpretation of the PGS Kit Landscape

This executive summary uses the supplied market definition-PGS Kit-and interprets it within the contemporary PGT-A and assisted-reproduction context. The assessment is organized around clinical workflow, technology, regulation, infrastructure, ethics, access, and regional variation rather than commercial sizing. Insights should be validated against current peer-reviewed evidence, professional-society guidance, national legislation, laboratory accreditation requirements, and product-specific regulatory documentation before being used for clinical, operational, or investment decisions. Because terminology and permitted use vary by jurisdiction, local expert review is essential.

Conclusion: Responsible Integration Will Determine Long-Term Relevance

PGS kits occupy a technically sophisticated but clinically nuanced position within assisted reproduction. Their value depends less on testing alone than on appropriate patient selection, validated laboratory processes, accurate interpretation, counseling, and integration with the full IVF pathway. Regional and national differences will continue to shape access and permitted use, while AI can improve workflow support if governed responsibly. Leaders that prioritize evidence, transparency, quality, privacy, and equitable patient care will be best positioned to develop sustainable clinical practice.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. PGS Kit Market, by Product

• 7.1. Introduction
• 7.2. Consumables
  • 7.2.1. Kits
  • 7.2.2. Reagents
• 7.3. Instruments
  • 7.3.1. Benchtop Instruments
  • 7.3.2. Real-Time Instruments

8. PGS Kit Market, by Technology

• 8.1. Introduction
• 8.2. Array Comparative Genomic Hybridization
  • 8.2.1. Agilent
  • 8.2.2. Thermo Fisher CGH
• 8.3. Next-Generation Sequencing
  • 8.3.1. Illumina
  • 8.3.2. Thermo Fisher
• 8.4. Real-Time PCR
  • 8.4.1. Applied Biosystems
  • 8.4.2. Rotor-Gene

9. PGS Kit Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Direct Sales
  • 9.2.1. Field Sales
  • 9.2.2. Online Sales
• 9.3. Distributors
  • 9.3.1. International Distributors
  • 9.3.2. National Distributors

10. PGS Kit Market, by Application

• 10.1. Introduction
• 10.2. Aneuploidy Detection
• 10.3. Genetic Disorder Detection
• 10.4. Structural Rearrangement Detection

11. PGS Kit Market, by End User

• 11.1. Introduction
• 11.2. Diagnostic Laboratories
  • 11.2.1. Hospital Labs
  • 11.2.2. Independent Labs
• 11.3. Fertility Clinics
  • 11.3.1. IVF Centers
  • 11.3.2. OBGYN Clinics
• 11.4. Hospitals
  • 11.4.1. Private Hospitals
  • 11.4.2. Public Hospitals

12. PGS Kit Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. PGS Kit Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. PGS Kit Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Agilent Technologies, Inc.
• 16.2. Aspira Women's Health Inc
• 16.3. BGI Group
• 16.4. Bio-Rad Laboratories, Inc.
• 16.5. Bioarray SL
• 16.6. BlueGnome Ltd
• 16.7. CooperSurgical Inc
• 16.8. Danaher Corporation
• 16.9. Eurofins Scientific SE
• 16.10. F. Hoffmann-La Roche AG
• 16.11. Fairfax Genetics Inc
• 16.12. Fulgent Genetics Inc
• 16.13. GenScript Biotech Corporation
• 16.14. Illumina, Inc.
• 16.15. Invitae Corporation
• 16.16. Laboratory Corporation of America Holdings
• 16.17. MGI Tech Co Ltd
• 16.18. Myriad Genetics, Inc.
• 16.19. Natera Inc
• 16.20. Oxford Nanopore Technologies Ltd
• 16.21. PerkinElmer Inc
• 16.22. QIAGEN NV
• 16.23. Quest Diagnostics Incorporated
• 16.24. Reprogenetics LLC
• 16.25. Sophia Genetics SA
• 16.26. Takara Bio Inc
• 16.27. Thermo Fisher Scientific Inc.

17. Key Experts